BioCentury on BioBusiness,
Table: Top biotech products
Back to the parent article
Monday, January 13, 2014
At least 46 drugs developed and marketed by biotech
companies are expected to have more than $500 million in 2013 sales. Of those,
26 are expected to bring in more $1 billion in annual sales. Seven drugs are
expected to cross the $500 million mark in 2013: Abraxane nab-paclitaxel;
Complera emtricitabine/tenofovir/rilpivirine; Elaprase idursulfase; Letairis
ambrisentan; Lialda mesalamine; Tecfidera dimethyl fumarate; and Xifaxan
Product sales as reported by companies listed below,
unless otherwise noted. Included are drugs developed by biotechs that were
acquired - Cephalon Inc.; Genentech Inc.; Genzyme Corp.; MedImmune LLC; Onyx
Pharmaceuticals Inc.; and OSI Pharmaceuticals LLC - but still maintain a
separate commercial presence from their acquirer. (A) 2013 sales projected from
2013 nine-month sales from UCB Group (Euronext:UCB) and sales for the
six months ended Sept. 30, 2013 from Astellas Pharma Inc. (Tokyo:4503);
(B) Sales of
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]